BioVaxys Technology Corp. is pleased to announce that interim results from its ongoing preclinical of BVX-1021, the Company's vaccine for SARS-CoV-1 ("SARS1") which is...
Moleculin Biotech, Inc., a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, reported preliminary interim...
